Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06625411 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

Study acronym: REVEAL-1
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 34 → 48 locationsv12
  2. Primary endpoint revised
    • Enrollment target: estimated 117 to confirmed 132
    • Primary completion date changed from estimate of Mar 1, 2026 to Feb 12, 2026
    • Secondary endpoints: 7 to 9
    v11
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 34 of 34 sites
    v10
  4. Study sites: 31 to 34v9
  5. Enrollment target: 84 to 117
    • Eligibility criteria expanded, about 48 words
    • Secondary endpoints reordered
    • Study description expanded, about 6 words
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 30 to 31v7
  2. Study sites: 17 to 30v6
  3. Study sites: 10 to 17v5
  4. Study sites revised (10)v4
  5. Study sites: 7 to 10v3
  6. Study sites: 2 to 7v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
Trial Details
NCT Number NCT06625411
Lead Sponsor Viridian Therapeutics, Inc.
Conditions
(from sponsor)		 Thyroid Eye Disease
Related terms Graves Ophthalmopathy
Enrollment 132 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov